Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Apr. 30, 2012
Apr. 30, 2011
Apr. 30, 2012
Apr. 30, 2011
Revenues:        
Clinical laboratory services $ 15,242 $ 13,809 $ 43,552 $ 38,477
Product revenues 9,574 10,935 28,819 31,356
Royalty and license fee income 1,133 1,083 4,302 5,380
Total revenues 25,949 25,827 76,673 75,213
Operating expenses:        
Cost of clinical laboratory services 9,204 8,268 26,728 23,333
Cost of product revenues 4,689 5,195 14,511 15,708
Research and development 1,588 2,053 4,916 5,831
Selling, general, and administrative 11,854 10,877 35,727 33,450
Provision for uncollectible accounts receivable 1,193 1,005 3,648 3,037
Legal 943 695 2,835 2,767
Total operating expenses 29,471 28,093 88,365 84,126
Operating loss (3,522) (2,266) (11,692) (8,913)
Other income (expense):        
Interest (18) 2 (6) 10
Other 15 71 94 147
Foreign currency gain (loss) 80 191 (243) 135
Loss before income taxes (3,445) (2,002) (11,847) (8,621)
Benefit (provision) for income taxes 34 (108) (279) (316)
Net loss $ (3,411) $ (2,110) $ (12,126) $ (8,937)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.09) $ (0.05) $ (0.31) $ (0.23)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 38,825 38,478 38,676 38,279